Welcome to our dedicated page for IOVANCE BIOTHERAPEUTICS SEC filings (Ticker: IOVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IOVANCE BIOTHERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IOVANCE BIOTHERAPEUTICS's regulatory disclosures and financial reporting.
IOVANCE BIOTHERAPEUTICS, INC. reported that Chief Commercial Officer Kirby Daniel Gordon had 10,001 Restricted Stock Units vest and convert into an equal number of common shares on August 10, 2026. Of these, 2,436 shares were delivered or withheld at $6.40 per share to satisfy mandatory tax withholding, which was not an open-market sale. Following the vesting, Gordon held 60,003 RSUs from the February 10, 2025 grant, with the remaining units scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Financial Officer Corleen M. Roche reported the vesting of 49,995 Restricted Stock Units on August 6, 2026, converting into an equal number of common shares. Of these, 21,238 shares were withheld at $6.21 per share to satisfy mandatory tax withholding, leaving 28,757 shares of common stock from this vesting. Following the transaction, she continues to hold 100,005 RSUs from the August 6, 2025 grant, separate from any other RSUs she holds.
State Street Corporation reported beneficial ownership of common stock of Iovance Biotherapeutics, Inc. This filing states that State Street and certain investment adviser subsidiaries collectively beneficially own 24,478,268 shares of Iovance common stock, representing 5.5% of the class.
The group reports 0 shares with sole voting or dispositive power, and 23,483,868 shares with shared voting power and 24,478,268 shares with shared dispositive power. Subsidiaries listed include SSGA Funds Management, Inc. and several State Street Global Advisors entities.
Iovance Biotherapeutics, Inc. updated its corporate presentation on August 6, 2026. The materials are used for presentations at healthcare conferences and in meetings with analysts, existing stockholders, and other interested parties.
The updated presentation is provided as Exhibit 99.1 and is incorporated by reference, making its contents part of the company’s public disclosures.
Iovance Biotherapeutics, Inc. reported Q2 2026 revenue of $99,313 (in thousands), compared with $59,952 a year earlier, driven by Amtagvi at $90,721 and Proleukin at $8,592 (each in thousands). First-half 2026 revenue was $170,743 versus $109,276 (in thousands).
Total Q2 costs and expenses were $151,218 (in thousands) versus $173,726, producing a loss from operations of $51,905 and a net loss of $47,315, or $0.11 per share, compared with a Q2 2025 net loss of $111,658, or $0.33 per share.
As of June 30, 2026, cash, cash equivalents, short-term investments and restricted cash totaled $303.7 million, and net cash used in operating activities for the first half was $132,915 (in thousands). The company raised $148,081 (in thousands) from common stock sales and believes existing capital will fund planned operations for at least twelve months. Amtagvi has approvals in the U.S., Canada and Australia, with additional marketing applications under review, while registrational trials continue in frontline advanced melanoma, previously treated advanced non-small cell lung cancer and select sarcomas.
Iovance Biotherapeutics reported record second-quarter 2026 revenue of $99.3 million, up 66% year over year, with roughly $91 million from Amtagvi and gross margin of 56%. Operating loss narrowed to $51.9 million and net loss to $47.3 million, while six-month net loss improved to $126.4 million from $227.8 million.
Management is reviewing its prior 2026 revenue guidance of $350–$370 million and plans to update it in the third quarter. The cash position, including cash, cash equivalents, short-term investments and restricted cash, was about $304 million as of June 30, 2026, which the company expects will fund operations into the second half of 2028.
The update also highlights progress across the TIL pipeline: Fast Track Designation for lifileucel in soft tissue sarcomas, advancing registrational programs in metastatic non-squamous NSCLC and advanced melanoma, next-generation gene-edited and IL-12 tethered TIL therapies, and expanding global Amtagvi access with recent approval in Australia and ongoing reviews in the UK and Switzerland.
BlackRock, Inc. reports a significant ownership position in IOVANCE BIOTHERAPEUTICS, INC. common stock. As of June 30, 2026, BlackRock and certain reporting business units beneficially owned 33,366,587 shares, representing 7.5% of the outstanding common stock. BlackRock has sole voting power over 32,842,318 shares and sole dispositive power over 33,366,587 shares, with no shared voting or dispositive power. The shares are held on behalf of various underlying clients, and no single underlying person is stated to have more than five percent of Iovance’s total outstanding common shares.
Iovance Biotherapeutics, Inc. updated its corporate presentation used for investor and conference meetings, outlining commercial progress, pipeline data, and financial guidance. The company highlights Amtagvi as the first FDA-approved one-time T cell therapy for solid tumors in second-line and later advanced melanoma, with more than 1,500 patients treated across commercial and clinical use.
The presentation reiterates Q2 2026 revenue guidance of $86M–$88M and full-year 2026 revenue guidance of $350M–$370M, supported by cash of about $319M as of March 31, 2026 and stated cash runway into 2028. Iovance reports over 90 authorized treatment centers, more than 200 million covered patient lives, and broad payer coverage generally aligned with clinical data and guidelines.
Clinical data summaries emphasize deep and durable responses in advanced melanoma, early but encouraging results in nonsquamous non-small cell lung cancer and soft tissue sarcomas, and proof-of-concept efforts in endometrial cancer. The company also details next-generation TIL and IL-2/IL-12-based programs intended to enhance efficacy and durability in solid tumors.
WEISER MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS director Michael Weiser received a grant of 90,316 deferred restricted stock units on June 16, 2026. Each unit represents one share of common stock under the 2018 Equity Incentive Plan. The units vest on the earlier of one year after the grant date or just before the next annual shareholder meeting, and delivery of shares is deferred until specific future events. Following this grant, Weiser holds 90,316 deferred restricted stock units directly.
IOVANCE BIOTHERAPEUTICS director Iain D. Dukes received a grant of 180,632 deferred restricted stock units (DRSUs) linked to the company’s common stock. The award was made at no cash exercise price under the company’s 2018 Equity Incentive Plan.
The DRSUs vest if Dukes continues providing service until the earlier of the first anniversary of the grant date or the day before the next annual shareholder meeting. Actual common shares are issued later, upon specified events such as board departure, a qualifying change in control, or ten years after the grant date.